Danaher Corporation $DHR Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund raised its stake in Danaher Corporation (NYSE:DHR) by 1,517.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 501,851 shares of the conglomerate’s stock after buying an additional 470,823 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Danaher were worth $114,884,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Landscape Capital Management L.L.C. boosted its position in shares of Danaher by 41.4% during the fourth quarter. Landscape Capital Management L.L.C. now owns 2,268 shares of the conglomerate’s stock worth $519,000 after buying an additional 664 shares during the period. Clear Street Group Inc. acquired a new position in shares of Danaher during the fourth quarter worth approximately $410,000. Dixon Mitchell Investment Counsel Inc. boosted its position in shares of Danaher by 2.1% during the fourth quarter. Dixon Mitchell Investment Counsel Inc. now owns 186,417 shares of the conglomerate’s stock worth $42,756,000 after buying an additional 3,819 shares during the period. Brown Advisory Inc. boosted its position in shares of Danaher by 11.1% during the fourth quarter. Brown Advisory Inc. now owns 3,487,241 shares of the conglomerate’s stock worth $798,304,000 after buying an additional 347,779 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Danaher by 3.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,628,052 shares of the conglomerate’s stock worth $830,534,000 after buying an additional 109,039 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. DZ Bank assumed coverage on Danaher in a research report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price objective for the company. Royal Bank Of Canada assumed coverage on Danaher in a research report on Thursday, May 14th. They set an “outperform” rating and a $200.00 price objective for the company. Morgan Stanley reduced their price objective on Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. Argus reduced their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Finally, TD Cowen reduced their price objective on Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $233.61.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Danaher Price Performance

Shares of NYSE:DHR opened at $179.95 on Friday. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The stock has a market cap of $127.37 billion, a price-to-earnings ratio of 34.81, a PEG ratio of 2.40 and a beta of 0.81. The stock’s 50 day moving average price is $180.93 and its 200 day moving average price is $204.78. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52.

Danaher (NYSE:DHR) last announced its earnings results on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the previous year, the company earned $1.88 earnings per share. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. Equities research analysts anticipate that Danaher Corporation will post 8.45 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s dividend payout ratio is currently 30.95%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.